Loading...
•
Dec 31, 2024
Teleflex Q4 2024 Earnings Report
Teleflex reported solid revenue growth in Q4 2024 but faced a GAAP EPS decline due to impairment charges.
Key Takeaways
Teleflex Incorporated reported Q4 2024 revenue of $795.4 million, up 2.8% year-over-year, with adjusted EPS rising 15.1% to $3.89. GAAP EPS declined to $(2.95) due to a $240 million non-cash goodwill impairment charge. The Interventional and Surgical segments showed strong growth, while Interventional Urology declined. The company reaffirmed its FY25 guidance with expectations for continued revenue growth and adjusted EPS improvements.
Revenue grew 2.8% year-over-year to $795.4 million, driven by strong Interventional and Surgical segments.
GAAP EPS declined to $(2.95) due to a $240 million non-cash goodwill impairment charge.
Adjusted EPS increased 15.1% to $3.89, reflecting strong operational performance.
Interventional Urology segment saw an 8.7% revenue decline due to market challenges.
Teleflex
Teleflex
Teleflex Revenue by Segment
Teleflex Revenue by Geographic Location
Revenue by Segment
Americas Segment Revenue
CapyFin.comEMEA Segment Revenue
CapyFin.comAsia Segment Revenue
CapyFin.comRevenue by Geographic Location
Vascular Access Revenue
CapyFin.comInterventional Revenue
CapyFin.comAnesthesia Revenue
CapyFin.comSurgical Revenue
CapyFin.comInterventional Urology Revenue
CapyFin.comOEM Revenue
CapyFin.comOther Revenue
CapyFin.com Forward Guidance
Teleflex expects modest revenue growth in FY25, with GAAP EPS forecasted between $8.85 and $9.25, and adjusted EPS between $13.95 and $14.35. The company remains focused on optimizing its portfolio and driving efficiency.
Positive Outlook
- Full-year adjusted EPS expected between $13.95 and $14.35.
- Revenue expected to grow between 1.0% and 2.0% on an adjusted constant currency basis.
- Acquisition of BIOTRONIK’s Vascular Intervention business to enhance Interventional portfolio.
- Operating efficiency improvements expected to support margin expansion.
- Planned $300 million share repurchase program to enhance shareholder value.
Challenges Ahead
- Foreign currency fluctuations expected to negatively impact revenue by 1.8%.
- Interventional Urology segment continues to face demand challenges.
- GAAP revenue growth guidance range of -0.4% to 0.7% indicates limited top-line expansion.
- Interest expense projected to remain elevated at approximately $83 million for FY25.
- Integration costs related to acquisitions may temporarily impact margins.
Revenue & Expenses
Visualization of income flow from segment revenue to net income